Congrats, Your Vaccine Works; Now, Who Will Buy It?
This article was originally published in Scrip
Executive Summary
Johnson & Johnson Inc. and its collaborators, including Bavarian Nordic AS, on April 19 published results of a Phase I trial showing their AdVac/MVA-BN prime-boost Ebola vaccine regimen produced an antibody response in 100% of healthy volunteers, which was sustained for eight months following immunization.